4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one manufacturers
- Setileuton
-
- $197.00
-
2026-05-11
- CAS:910656-27-8
- Purity: 99.31%
- Supply Ability: 10g
|
| | 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one Basic information |
| Product Name: | 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one | | Synonyms: | MK-0633;4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one;4-(4-fluorophenyl)-7-[[[5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl]amino]methyl]chromen-2-one;2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-;Setileuton, 10 mM in DMSO;Setileuton | | CAS: | 910656-27-8 | | MF: | C22H17F4N3O4 | | MW: | 463.38 | | EINECS: | | | Product Categories: | | | Mol File: | 910656-27-8.mol | ![4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one Structure](CAS2/GIF/910656-27-8.gif) |
| | 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one Chemical Properties |
| Melting point | 92.9-94.3 °C | | Boiling point | 609.6±65.0 °C(Predicted) | | density | 1.478 | | pka | 9.65±0.29(Predicted) |
| | 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one Usage And Synthesis |
| Uses | Setileuton (MK-0633) is an inhibitor for 5-lipoxygenase, that inhibits the oxidation of arachidonic acid by recombinant human 5-LO, and the production of LTB4 in calcium ionophore-stimulated human whole blood, with IC50 of 3.9 and 52 nM, respectively[1]. | | in vivo | Setileuton (5 mg/kg, i.v.; or 20 mg/kg, p.o., single dose) exhibits good pharmacokinetic profils with a half-time T1/2 of 3.3 h, and a bioavailability of 66% in rat model[1]. | | References | [1] Ducharme Y, et al., The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor. ACS Med Chem Lett. 2010 Apr 13;1(4):170-4. DOI:10.1021/ml100029k |
| | 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one Preparation Products And Raw materials |
|